MGMT and astrocytoma (excluding glioblastoma): Additionally, we hypothesize that the efficacy of TMZ in G4 astrocytoma may improve with the use of PRMT5 inhibitors, irrespective of the methylation status of MGMT-promoter or IDH mutational status.